FDA gave the light to Bremelanotide (marketed as Vyleesi) in June 2019 for treating women with HSDD—a condition characterized by libido—and stands out from other remedies due, to its unique administration and side effects profile. This medicine works by focusing specificallyon the melanocortin 1 and 4 receptors found in the hypothalamus of the brain, which play a role, in regulating sexual behavior. Through stimulating these receptors with bremelanotide activates dopamine release helping to regulate signals connected to sexual desire. Usually consumed, around 45 minutes prior to expected activity this medication has been proven to enhance arousal and alleviate the anxieties commonly linked with issues; however research is still ongoing to determine the best timing, for its use.
Hall, K. S. K., & Binik, Y. M. (2020). Principles and practice of sex therapy (6th ed.). The Guilford Press.
Paauw, D. (2024). Newer outpatient therapies and treatments, an issue of Medical Clinics of North America. Elsevier.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about PT-141 by Dragon Pharma, consult with your doctor or healthcare professional.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Home
